4BB 4basebio Plc

 
TIDM4BB 
 
18 June 2021 
 
                             4basebio UK Societas 
 
                         ("4basebio" or the "Company") 
 
                      Annual General Meeting 2021 ("AGM") 
 
Following the UK government announcement on 14 June 2021 that lockdown measures 
will not be withdrawn by the time of the AGM, the Company confirms that it 
intends to hold its 2021 AGM with only the minimum number of shareholders 
present as required to form a quorum under the Company's Articles of 
Association, and who (being officers or employees of the Company) are essential 
for the business of the AGM to be conducted. 
 
As set out in the notice of meeting, the AGM will be held on 30 June 2021 at 
9.00am. In view of the continuing risk posed by COVID-19 and having regard to 
their own safety and that of others, shareholders and their representatives are 
respectfully asked not to seek to attend the AGM in person. To ensure the 
safety of the limited number of people whose attendance is essential, we do not 
propose to allow other shareholders or their representatives to gain access to 
the AGM venue on the day. 
 
In order to ensure shareholders' votes are counted, despite these restrictions, 
the Board strongly encourages shareholders to exercise their right to vote by 
appointing the chairman of the AGM as their proxy to vote at the AGM in 
accordance with their instructions. To appoint a proxy, please complete the 
form of proxy and send it to our registrar, Computershare Investor Services 
PLC. CREST members who wish to appoint a proxy or proxies for the AGM (and any 
adjournment(s) thereof) through the CREST electronic proxy appointment service 
may do so by using the procedures described in the CREST Manual (available via 
www.euroclear.com). Proxy appointments must be received by Computershare 
Investor Services PLC no later than 9:00am on 28 June 2021. If two or more 
valid forms of proxy are delivered in respect of the same share, the one which 
was delivered last (regardless of its date or the date of its execution) will 
be valid. Further details are set out in the notice of meeting and in the form 
of proxy. 
 
We, as your Board, are committed to open dialogue with our shareholders and 
remain very mindful of ensuring that shareholders have an opportunity to engage 
with us. Shareholders are encouraged to submit questions in advance of the AGM 
or raise matters of concern as a shareholder by emailing the Company Secretary 
using the email address provided in the notice of meeting. Answers to questions 
that are of common interest will be published on the Company's website.  Also, 
as previously announced, the AGM will be followed by a presentation from the 
Company through the Investor Meet Company platform on 1 July 2021 at 10.00am. 
Investors can sign up to Investor Meet Company for free and register interest 
here: https://www.investormeetcompany.com/4basebio-uk-societas/ 
register-investor 
 
For further enquiries, please contact: 
 
4basebio UK Societas                                                                      +44 (0)12 2396 7943 
 
Heikki Lanckriet, CEO 
 
Cairn Financial Advisers LLP (Nominated Adviser)                                          +44 (0)20 7213 0880 
 
Jo Turner / Sandy Jamieson 
 
finnCap Ltd (Broker) 
 
Geoff Nash/Richard Chambers/Charlotte Sutcliffe                                           +44 (0)20 7220 0500 
 
Walbrook                                                                                  +44 (0)20 7933 8780 
PR 
 
Anna Dunphy / Paul McManus                                     Mob: +44 (0)7876 441 001 / +44 (0)7980 541 893 
 
 
Notes to Editors 
 
4basebio (AIM: 4BB) is a specialist life sciences group focused on therapeutic 
DNA for gene therapies and DNA vaccines and providing solutions for effective 
and safe delivery of these DNA based products to patients. It is the intention 
of the Company to become a market leader in the manufacture and supply of high 
purity, synthetic DNA for research, therapeutic and pharmacological use. The 
immediate objectives of 4bb are to validate and scale its DNA synthesis and 
advance its collaborations to facilitate the functional validation of its DNA 
based products and gene delivery solutions. 
 
The Company divested from 4basebio AG ("4bb AG"), a German company listed on 
the Prime Standard segment of the Frankfurt Stock Exchange, following the 
disposal by 4bb AG (then named Expedeon AG) of its proteomics and immunology 
business to AIM-quoted Abcam plc in January 2020 for ?120million. Following the 
disposal, 4bb AG retained its genomics business which owned and licensed 
certain intellectual property including its proprietary, patent-protected 
technology, TruePrimeT. This is the foundation for building the Company's 
synthetic DNA manufacturing business which 4bb AG transferred to the Company 
along with funding to continue the Company's development and investment. 
 
 
 
END 
 
 

(END) Dow Jones Newswires

June 18, 2021 02:00 ET (06:00 GMT)

4basebio (LSE:4BB)
Historical Stock Chart
From Apr 2024 to May 2024

4basebio (LSE:4BB)
Historical Stock Chart
From May 2023 to May 2024